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jligh-Sensitivity Serum Calcitonin Assays Applied to Screening for
Xhyroid C-Cell Disease in Multiple Endocrine Neoplasia Type 2A*

ivlichael M. Kaplan,* Glenn M. Stall,* Timothy Cummings,' Andrew MacAulay,*
Philippe Motte,* Hubert J. Wolfe,^ Seymour Reichiin,* and Arman H. Tashjian, Jril

Two serum calcitonin assays with sensitivities <, 10 pglmL were compared to our standard
radioimmimoa.ssay (sensitivity 100 pg/mL) in multiple endocrine neoplasia type 2A (MEN 2A)
screening. Values from the Nichols displacement radioimmunoas.say averaged 38%: higher than
values from the CIS immunoradiometric assay; values from hoth were highly correlated, r = 0.845. In
three individuals, both oftlie newer as.says revealed abnormalities in pentagastrin tests three to four
years before abnormalities were detected by the standard assay. Pentaga.strin tests after total
thyroidectomy were assayed by the newer methods in patients with medullaij thyroid carcinoma
(MTC) diagnosed at initial testing (group I); in patients with early MTC diagnosed hy prospective
screening (group ll); and in patients with pure C-cell hypei-ptasia detecied by pro.speclive screening
(group III). At least 64% of group I. at least 25% of group II, but none of group III had detectable
postoperative C-cell function. Conclusions: I) The previous estimate of 12 years as median age of
onset of C-cell di.sea.se in MEN 2A is probably three to four years too old. 2) Patients diagnosed with
early MTC by screening had not necessarily skipped a preneoplastic phase of C-cell hyperplasia. At
least some early di.sease was not detected hy the standard assay. Higher .sensitivity assays should
improve screening for C-cell disease by earlier disea.se detection. 3) Biochemical cure by thyroidectomy after the development of MTC is not as frequent as previously thought, but the apparent
cure rate ofpure C-cell hyperplasia remains 100%\ (Henry Ford Ho.sp Med J 1992:40:227-31)

A

large kindred with multiple endocrine neoplasia type 2A
(MEN 2A), the J-kindred, has been the subject of a longterm study begun in 1969 to identify individuals with C-cell disease and medullary thyroid carcinoma (MTC) in the preinvasive
stage. The disease is inherited in autosomal dominant fashion
with a theoretical probability that each child of a gene carrier has
a50:50chance of developing MTC. During the first Iwo years of
the study, 12 family members were found to have abnormal
plasma calcitonin (CT) respon.ses to calcium infusion as measured by radioimmunoassay (1,2); each was operated upon and
found to have MTC (3). A prospective study of individuals at
risk was then initiated in which stimulated CT secretion was determined at one- to two-year intervals. CT-secretion screening
tests, with calcium as the secretagogue during the first few years
and pentagastrin more recently, have identified many patients
who have only C-cell hyperplasia or microscopic foci of carcinoma in a gland with C-cell hyperplasia and who have no evidence of metastatic disease (4-7). Similar studies have been reported by other groups (8-10). By pooling test results frotn the
J-kindred with a large number of other kindreds, it has also been
possible to calculate the probability of developing C-cell disease as a function of age (11,12). Our screening protocol is
started at 5 years of age for children at risk. C-cell abnormalities
are assessed by annual CT measurernents before and after pentagastrin stimulation; surgery is advised after two successive abnormal tests. Almost all family members so advised have had
thyroidectomy within a few months.
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Although the majority of individuals with C-cell disease have
been idendfied by prospective screening while in the premetastatic stage, this program has not identified every patient in the
preneoplastic stage. Of the individuals found to have developed
C-cell disease during prospective screening between 1972 and
1989.11 of 24 had intrathyroidal foci of medullary carcinoma at
the time of surgery (6). This finding suggests that the premalignant phase of C-cell hyperplasia (7) is absent or lasts less than
two years in some affected persons, or, altematively, that the
screening test might be too insensitive to detect the earliest
stages of C-cell hyperplasia. Another uncertainty is that the likelihood of cure by total thyroidectomy and central node dissection, the standard surgical procedure for C-cell disease (13,14),
is not known for tho.se patients treated after they develop local-
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ized foci of medullary carcinoma. Since most patients survive
for many decades with known residual MTC, CT measurements
must be used as surrogates for mortality data.
The CT radioimmunoassay (1,2) used since the inception of
the J-kindred screening program has a sensitivity of 100 to 200
pg/mL. Two additional CT assays have become available that
have .sensidvity limits of about 10 pg/mL. It was anticipated that
the use of more sensitive assays might permit the detecdon of affected individuals with C-ced disease at an earlier stage. Since
1986, results from these newer assays have been compared with
results obtained with the standard assay in screening the J-kindred and another MEN 2A family, the C-kindred. By the use of
the new CT assays in the prospective screening program and
from measurements of CT in archived frozen serum samples
from the J-kindred, evidence has emerged that the age of onset
of C-cell hyperplasia may be earlier than previously thought,
and that the cure rate in patients with minute foci of MTC may
not be as high as our earlier findings indicated. These findings
have important implicadons about the biology of MEN 2A and
must be taken into account when calculadng risks of genetic
susceptibility when used in conjunction with analysis of polymorphic gene markers (15-18).

Patients and Methods
The J-kindred has been described in detail (3-7). The C-kindred, another MEN 2A family, is of French origin with family
members living in France, the Quebec province of Canada, and
Massachusetts with MTC occurring in three generations. Two
affected individuals also have had pheochromocytomas and another affected woman is said to have had bilateral adrenal tumors, although documentation of her adrenal pathology is unavailable. No C-kindred member is known to have parathyroid
disease. We have studied one branch of the C-kindred since
1988. All patients in this study who have been treated surgically
have had a total thyroidectomy and central node dissection.
The pentagastrin stimuladon test consists of an intravenous
bolus injection of pentagastrin (Peptavlon, Ayerst), 0.5 (J-g/kg
body weight, with blood samples taken immediately before and
1, 2, and 5 minutes afterward.
The standard CT radioimmunoassay has been described
(1,2). Upper limits of normal for basal- and pentagastrin-stimulated serum CT concentrations are 550 pg/mL and 750 pg/mL,
respecdvely. The newer assays are a commercially available kit
from Nichols Institute Diagnostics (San Juan Capistrano, CA)
and a kit commercially available in Europe from Intemational
CIS (Gif-sur-Yvette, France). The Nichols assay is based on antiserum from a goat immunized with synthetic human CT (19)
and is a competitive radioimmunoassay. The sensitivity for this
assay is 1 to 3 pg/mL. The upper limits of normal for basal serum CT concentrations, as given by the manufacturer, are 36 pg/
mL for males and 17 pg/mL for females. The upper limits of normal for serum CT concentrations after pentagastrin stimulation,
as given by the manufacturer, are 106 pg/mL for males and 29
pg/mL for females. Basal semm CT concentrations were found
to be above the lower limit of sensitivity in > 99% of our samples assayed with the Nichols kit. Most patients treated by total
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thyroidectomy had basal serum CT values of < 10 pg/inL by the
Nichols assay with no change after pentagastrin injection.
The CIS assay is a sandwich assay using two monoclonal antibodies raised against a synthetic pepude with 1 to 32 amino
acid sequence of the mature monomeric form of hurnan CT
(20,21). The sensitivity for the CIS assay is 6.7 pg/mL. Using
the CIS assay, both norrnal males and normal females have basal
values < 10 pg/mL and values up to 30 pg/mL after pentagastrin
stimulation [(22) and manufacturer's package information]. In
our studies, 39 (83%) of 47 clinically unaffected members ofthe
J- and C-kindreds were found to have basal serum CT values below 6.7 pg/mL, and 44 (94%) of 47 had values < 10 pg/mL.
Three males from unaffected branches of the J-kindred had
slightly elevated basal serum CT concentrations of 16 to 39 pg/
mL, but showed noriseafter pentagastrin stimulation. The possible significance ofthese values is discussed later.
Padents with C-cell disease were considered to have a biochemical cure after total thyroidectomy when both their basal
and peak pentagastrin-stimulated serum CT concentrations
were less than 10 pg/mL, or when their basal CT level was between 10 and 20 pg/mL and less than a 50% increa.se occurred
after pentagastrin stimulation. In some patients, the Nichols and
CIS assays gave discrepant results, and only basal serum CT
measurements were available in one case; the findings in these
cases will be noted specifically.
Archived samples used for retrospective analysis were slored
al -70 °C and had, in most cases, been thawed only once at the
time oftheir initial measurements by the standard assay.

Results
Comparison of values obtained by the Nichols and CIS
assays
CT concentrations by both of the high-sensidvity assays were
compared in 227 serum samples taken from 60 pentagastrin
stimulation tests in which the CIS assay gave a measurable
value. Most ofthese samples were from known affected individuals, inasmuch as most known unaffected individuals had indeterminate values by the CIS assay. Values obtained with the
Nichols assay were higher than those obtained with the CIS assay in 85% of samples. The mean rado of Nichols:CIS values
was 1.38, with 95% confidence limits of 1.22 to 1.56 for the
mean. Values from both assays were highly correlated from < 10
to > 2,000 pg/mL, with r = 0.845 for log transformed values, P <
0.0001.
Sixty-seven samples were available in which serum CT concentradon was measurable by the standard assay and in which
values from the other two assays were determined. Using logtransformed data, the correlation between the values from the
standard assay between 210 and 14,000 pg/mL and Nichols assay values was r = 0.585 (P < 0.001) and between standard assay
and CIS assay values was r = 0.615 (P< 0.001). Values from the
Nichols assay were up to 45% higher than those from standard
assay in seven samples and were lower in the other 60. Values
from the CIS assay were lower than those from the standard assay in all samples but one, in which the values were equal.
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Clinical observations
CT measurements in preoperative serum samples—Between
1986 and 1989, three individuals were found to have abnormal
CT secretory response results which revealed clinically important discrepancies among the assays. One of these (Figure) was
a 17-year-old female who had been screened regularly since age
7 and had normal basal CT levels and pentagastrin-stimulated
CT levels by the standard assay in every test. In archived serum,
her basal and sdmulated CT values by the Nichols assay were, in
retrospect, normal through age 12'/2 years. Over the next year
there was a sharp rise to an abnormal level in the stimulated CT
value, measured by the Nichols assay, with further increases
during the following three years. In the last test, the basal serum
CT concentration by the Nichols assay was only minimally elevated (22 pg/mL), although the pentagastrin-sfimulated level
was as much as six times normal. Basal serum CT concentrafions measured by the CIS assay (normal < 10 pg/mL) were
slightly elevated in all available samples: the basal values were
15 pg/inL at age 7, 29 pg/mL at age 17, and between 10 and 35
pg/mL in the intervening tests (values not shown in the Figure).
The stimulated-serum CT concentradons were also abnormal by
the CIS assay in all of the avadable samples, but the elevations
were minimal through age 12'/2. Like the Nichols assay, the CIS
assay showed a marked rise in stimulated-serum CT levels
thereafter. Total thyroidectomy was performed at age 17'/2; Ccell hyperplasia with several small medullary carcinomas, up to
5 mm in diameter, were found within the thyroid gland.
Two other patients had results similar to the paUent illustrated
in the Figure, although one had been lost to the study and had
had no tests for five years before surgery. Retrospective measurements by the newer assays showed marked elevations of
sdmulated-serum CT concentrations for three to four years during which the standard assay had given normal values. Both
glands showed C-cell hyperplasia and small bilateral foci of
MTC.
Postoperative serum CT measurements—^Individuals with
pathologically proven C-cell disease were classified into three
groups for analysis of the biochemical outcome of surgery.
Group I included 17 J-kindred and C-kindred members who
had abnormal pentagastrin tests the first time they were tested
(i.e., before prospective screening). The first tests in the J-kindred members used the standard assay, while the finst tests in the
C-kindred members used the Nichols assay. In this group, three
patients died of causes unrelated to their MEN 2A diseases before our use ofthe Nichols and CIS assays. Of the other 14, four
met criteria for biochemical cure, and 10 had clearly measurable
postoperative semm CT concentrations by both the Nichols and
CIS assays. In five ofthe 10, the basal serum CT concentrations
were normal by both assays, with only the pentagastrin-stimulation test showing evidence of residual C-cell function (stimulated values between 36 and 450 pg/mL). One other of those
with measurable serum CT postoperatively had advanced renal
failure, and basal seruin CT concentrations > 100 pg/mL, but
less than a 50% increment after pentagastrin sdmulation. Because renal fadure is known to cause elevated serum CT concentrafions in the absence of C-cell disease, the meaning of the elevated level in this padent is unclear. Thus, nine of 14 tested pa-
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Figure—Serum CT concentrations in a female J-kindred memher measured in archived serum samples. Samples were stored
at-70 °C f'or 1 month to 10 years before the measurements were
performed. Stimulated values for each pentagastrin test are the
highest ofthe values in the serum samples taken 1,2, and 5 minutes after pentagastrin injection. The horizontal litie indicates
the upper limit of normal for stimulated values in females hy the
Nichols assay. The upper limit of normal for stimulated values
by the CIS assay is 10 pg/mL. Solid circles and squares denote
basal and .stimulated values, respectively, hy the Nichols assay.
Open circles denote stimulated values hy the CIS assay. For visual clarity, basal concentrations hy the CIS assay are not
shown, hut are discussed in the text.

tients in group I did not achieve biochemical cure after total thyroidectomy and the status of one is uncertain, although only two
had known anatomic sites of residual MTC. The median time
between surgery and the most recent CT testing was 18 years
(range 1 to 21 years).
Group II included 12 J-kindred padents whose abnormality
was found by prospective screening and who had at least one
microscopic focus of MTC at the time of thyroidectomy. All
were tested with the newer CT assays postoperafively, with a
median time between surgery and the most recent CT testing of
13.5 years (range 1 to 16 years). Seven met the criteria for biochemical cure by both the Nichols and CIS assays. Two met criteria for biochemical cure by the CIS assay but had detectable
pentagastrin-sfimulated CT levels by the Nichols assay (18 pg/
mL and 53 pg/mL). The other three had detectable basal- and
stimulated-serum CT concentrations by both assays (basal values between 12 and 37 pg/mL, stimulated values between 33
and 293 pg/mL). Of the three patients who had evidence of Ccell disease several years before surgery when their archived serum samples were retrospectively tested, one had residual C-cell
function according to the Nichols assay and the other two had
residual C-cell function by both assays.
Group III included 13 J-kindred patients whose abnormality
was found by prospective screening and who had only C-cell
hyperplasia at the time of thyroidectomy. The median length of
time between thyroidectomy and the most recent CT testing was
15 years (range 7 to 18 years). In group III, two patients were
lost to follow-up, eight met criteria for biochemical cure by both
assays, and two met criteria for biochemical cure by the Nichols
assay but were not tested by the CIS assay. The remaining
woman had a normal basal-serum CT concentration by both as-
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says but did not receive pentagastrin because she was pregnant.
Thus, in group III, no patient had evidence of abnormal residual
C-cell function after surgery, although follow-up was incomplete.

Discussion
In this study, two high-sensitivity CT immunoassays were
applied to the screening of individuals in MEN 2A kindreds for
thyroid C-cell disease and results compared with studies using a
standard assay. Both newer assays are capable of measuring serum CT concentrations 10- to 30-fold lower than the sensitivity
limit of the CT assays available prior to about 1986, including
the standard assay used in screening the J-kindred since 1969.
The results obtained with the Nichols and CIS assays were qualitatively similar, though some quanfitadve differences were
found. The Nichols assay gave results that were generally higher
than those of the CIS assay. This finding is not surprising. The
Nichols assay uses an antiserum raised against synthetic human
CT, which may well recognize not only the intact form of CT but
other molecular species as well. The CIS assay is designed to
measure only the mature, amidated monomeric form of CT
which accounts for less than half of the total immunoreactive
hormone in the circulation under basal conditions. The mature
monomer predominates in the seruin of patients with MTC after
pentagastrin .stimulation (23). The CIS assay detects CT in some
padents who have renal failure or various neuroendocrine, lung,
and other malignancies (24); CT precursors do not crossreact in
the assay (25). Three unaffected men in our MEN 2A kindreds
had slighdy elevated basal CT levels by the CIS assay, with no
significant rise after pentagastrin. All are clinically well, though
they may conceivably have an undetected disease that raises the
semm CT level, or have semm constituents, other than CT, that
interfere in the CIS assay. It would appear that the standard CT
assay recognizes more forms of the circulating hormone than either of the other methods.
Semm CT measurements in archived preoperative serum
samples from MEN 2A padents with proven C-cell disease suggest that several affected individuals had developed abnormal
C-cell function three to four years before detection by the standard assay. Similarly, Guilloteau et al (22), using the CIS assay
to study one MEN 2A kindred, identified four cases of MTC in
whom an older competitive radioimmunoassay method did not
detect any abnormality. Thus, previous estimates of the age of
onset of C-cell disease in MEN 2A may be too high by three to
four years or more; the median age of onset may be closer to 8 or
9 years than 12 years (11,12). Consequently, negative test results by a high-sensitivity CT assay may provide more reassurance to a young adult than could be given with the previously
available assays. For example, a 26-year-old individual with a
normal pentagastrin test is probably closer to having a 5% risk
of carrying the MEN 2A gene than the 10%riskpreviously esfimated (11,12).
Another implicadon ofthe retro.spective measurements is that
the presence of intrathyroidal foci of MTC in about 50% of the
J-kindred at the dme of surgery is likely to reflect the fact that
clear elevations in serum CT in the earliest stages of C-ceU dis-
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ease were not detected by the previously available assays. It is
likely, therefore, that a higher percentage of patients will be
identified in the premalignant phase of their C-cell disease when
high-sensidvity CT assays are employed. Even with the increased sensitivity of the newer serum CT assays, it is still the
case that pentagastrin stimulation reveals abnormal C-cell funcdon up to several years before the basal serum CT concentration
becomes abnormal (2-7).
Resuhs from the high-sensitivity CT assays also modify previous conclusions (6) about the impact of total thyroidectomy
on C-cell disease in MEN 2A. With the criteria we used for biochemical cure, group III individuals with pure C-cell hyperplasia treated by total thyroidectomy have an excellent cure rate.
None tested thus far has evidence of residual abnormal C-cell
function, though follow-up is incomplete. At the other extreme,
only four of 14 group 1 patients, in whom MTC was present at
initial testing before prospecdve screening began, met current
criteria for biochemical cure. Since only one padent was cured
of the three who died before we started using the newer assays,
and one living patient has an uncertain status, the overall cure
rate in this group is only about one-third. Previous esdmates using the standard CT assay, supplemented by the Nichols assay in
a few patients, were that half of the patients in this group were
cured (6).
In group II patients, who had intrathyroidal MTC and C-cell
hyperplasia detected by prospective screening, results of highsensitivity CT testing suggest that a substantial minority of patients fail to achieve biochemical cure after total thyroidectomy.
There were three or five such cases out of 12 depending on the
significance attached to detectable stimulated-serum CT levels
by the Nichols assay only. The reason that this conclusion differs from previously reported findings in the J-kindred (6) is that
three of the five individuals in this group with evidence of residual C-cell function had their abnormality detected and the other
two had their first abnormal follow-up tests after the previous
analysis was completed.
The significance of postoperative residual C-cell function in
relation to prognosis is not yet known. The group II patients who
had detectable CT concentrations were 20 to 27 years old at the
time ofthis analysis and had no other evidence of residual MTC.
In the oldest generation of the J-kindred studied (diagnosed before any screening was started), five of seven affected individuals died of MTC, with ages at death of 51 to 69 years. Thus, diagnosis and treatment of C-cell disea.se in MEN 2A at the stage of
C-cell hyperplasia appears to be the most effecdve management, but diagnosis and treatment in the stage of microscopic intrathyroidal MTC is probably advantageous also. However, an
additional 40 years of observation may be needed to provide a
direct test of this hypothesis.
On the basis of our findings, we recommend the use of highsensitivity CT assays in MEN 2A screening programs. Admittedly, the frequency of a false-positive diagnosis when these
tests are used is as yet unknown. Prospective screening is particularly demanding in this regaid, because the goal is diagnosis
early in the course of the disorder. Using the standard assay,
there has been one definite false-posidve diagnosis in 36 patients subjected to thyroidectomy in the J-kindred and three ad-
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didonal patients (included in our group III) whose thyroid histopathology was mild diffuse C-cell hyperplasia but whose genefic linkage studies (16) predict a probability of less than 1%
that they carry the MEN 2A gene (26). To date, seven untreated
patients had abnormal pentagastrin tests by the newer CT assays. Ad had subsequent thyroidectomy; histopathology was
microscopic MTC in four and diffuse C-cell hyperplasia in
three. Thus, diagnosfic accuracy of these high-sensitivity assays
is excellent so far, but only a small number of patients have had
surgery to date. The combination of genetic screening for the
MEN 2A carrier state (15-18), when it becomes available, together with a high-sensifivity CT assay in prospective screening
programs, should lead to greater accuracy in the preoperative diagnosis of C-cell disease than either method alone.
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